Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-18 Earnings release - Q2 2026

More about the company

Market Cap	6.68M 0 5.79M 5.42M 4.95M 9.31M 637M 9.46M 63.87M 24.94M 319M 25.06M 24.52M 1.06B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	6.68M 0 5.79M 5.42M 4.95M 9.31M 637M 9.46M 63.87M 24.94M 319M 25.06M 24.52M 1.06B	EV / Sales 2026 *	4.5x	EV / Sales 2027 *	2.57x
Free-Float	78.43%	Yield 2026 *	-	Yield 2027 *	-

07-27	L.I.A. Pure Capital Ltd Delivers an Email to Evogene Ltd	CI
07-22	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
07-22	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
07-10	L.I.A. Pure Capital Sends Letter to Evogene	CI
07-08	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
06-24	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
05-20	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
05-18	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
04-24	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
04-02	Evogene reports receipt of Nasdaq minimum bid price notification	RE

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	Evogene : Aegis Capital Starts Evogene at Buy	MT
01/12/20	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

12:01pm	Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation	PR
07-30	Evogene Schedules Second Quarter 2026 Financial Results Release	PR
07-22	Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	PR
07-08	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
06-02	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	30/11/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	31/12/2021

Evogene Ltd Share Price TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news : Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	02/06/2010
Sarit Firon CHM	Chairman	60	31/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	6.68M
LONZA GROUP AG	-1.82%	-1.99%	+1.67%	+13.48%	49.24B
REVOLUTION MEDICINES, INC.	-0.64%	-2.17%	+457.16%	+568.97%	43.3B
BEONE MEDICINES AG	-3.07%	-0.95%	+11.39%	+68.99%	40.48B
IQVIA HOLDINGS INC.	-0.78%	+0.36%	+26.48%	+8.83%	39.75B
CELLTRION, INC.	0.00%	+3.59%	+20.51%	+48.00%	32.67B
ASCENDIS PHARMA A/S	-0.85%	-4.01%	-	-	16.23B
MEDPACE HOLDINGS, INC.	-0.29%	-1.76%	+26.52%	+118.47%	16.24B
EUROFINS SCIENTIFIC SE	+0.63%	+1.00%	+4.41%	+22.27%	14.04B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.44%	+4.76%	+79.86%	+29.19%	13.43B
Average	-0.77%	+2.30%	+78.50%	+109.77%	29.49B
Weighted average by Cap.	-1.09%	+2.71%	+94.82%	+131.00%

	2026 *	2027 *
Net sales	1.48M 0 1.29M 1.21M 1.1M 2.07M 142M 2.1M 14.2M 5.54M 70.9M 5.57M 5.45M 237M	2.6M 0 2.25M 2.11M 1.93M 3.62M 248M 3.68M 24.88M 9.71M 124M 9.76M 9.55M 414M
Net income	-16.69M -0 -14.46M -13.56M -12.36M -23.26M -1.59B -23.64M -160M -62.33M -797M -62.65M -61.29M -2.66B	-13.92M -0 -12.06M -11.31M -10.31M -19.4M -1.33B -19.71M -133M -51.98M -665M -52.24M -51.11M -2.22B
Net Debt	-	-